ARM Innovation Hub
RealVNC mid banner careers
Advertisement: Mobas mid banner
RealVNC mid-banner general
Barr Ellison Solicitors – commercial property
Advertisement: Bradfield Centre mid
Advertisement: KISS
Advertisement: Lynch Wood Park
Advertisement: Stansted Travel Show
Advertisement: EY
Advertisement: CPL mid banner
Advertisement Cambridge China Centre
Advertisement: Bridge Fibre mid
Advertisement: Cambridge Network
22 May, 2012 - 08:31 By News Desk

Isogenica pushes into Japan

Isogenica CEO, Dr Kevin Matthews

Isogenica, based at the heart of the Cambridge UK BioMedTech cluster, has made a decisive move to open up Japan as a market for its innovative technology for antibody, protein and peptide design.

The Chesterford Research Park company has appointed CTC Laboratory Systems Corporation (CTCLS) of Tokyo to represent the business in Japan.

CTCLS is a leading force in the pharmaceutical research market in Japan and has been tasked with finding a new customer base in the territory for Isogenica.

Isogenica CEO, Dr Kevin Matthews, believes the move is essential as the company pushes for genuine global coverage.

He said: “The appointment of CTCLS is an important milestone for Isogenica and ensures that we can support our key customers in all the major world markets.

“We understand that direct personal contact, taking account of cultural and language differences, is fundamental to developing strong customer relationships.

“I am confident that CTCLS is the best organisation to represent us and look forward to working with them to introduce Isogenica to the Japanese market as a whole – as well as following-up on specific customer opportunities.”

Founded in 2000, Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies. It is regarded as having developed a unique capability in the field of protein engineering.

Isogenica's CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.

As a member of ITOCHU Techno-Solutions Corporation (CTC), CTCLS has evolved into one of Japan's leading solution providers, specialising in the integration of R & D support systems for life science companies.

With end-to-end solution capability, CTCLS deals with pharmaceutical, chemical and food manufacturers, as well as universities and public offices, and offers a wide-range of products and services that cover every stage of R & D activities.

Add new comment

Newsletter Subscription

Stay informed of the latest news and features